Unknown

Dataset Information

0

Prevention of carcinogen and inflammation-induced dermal cancer by oral rapamycin includes reducing genetic damage.


ABSTRACT: Cancer prevention is a cost-effective alternative to treatment. In mice, the mTOR inhibitor rapamycin prevents distinct spontaneous, noninflammatory cancers, making it a candidate broad-spectrum cancer prevention agent. We now show that oral microencapsulated rapamycin (eRapa) prevents skin cancer in dimethylbenz(a)anthracene (DMBA)/12-O-tetradecanoylphorbol-13-acetate (TPA) carcinogen-induced, inflammation-driven carcinogenesis. eRapa given before DMBA/TPA exposure significantly increased tumor latency, reduced papilloma prevalence and numbers, and completely inhibited malignant degeneration into squamous cell carcinoma. Rapamycin is primarily an mTORC1-specific inhibitor, but eRapa did not reduce mTORC1 signaling in skin or papillomas, and did not reduce important proinflammatory factors in this model, including p-Stat3, IL17A, IL23, IL12, IL1?, IL6, or TNF?. In support of lack of mTORC1 inhibition, eRapa did not reduce numbers or proliferation of CD45(-)CD34(+)CD49f(mid) skin cancer initiating stem cells in vivo and marginally reduced epidermal hyperplasia. Interestingly, eRapa reduced DMBA/TPA-induced skin DNA damage and the hras codon 61 mutation that specifically drives carcinogenesis in this model, suggesting reduction of DNA damage as a cancer prevention mechanism. In support, cancer prevention and DNA damage reduction effects were lost when eRapa was given after DMBA-induced DNA damage in vivo. eRapa afforded picomolar concentrations of rapamycin in skin of DMBA/TPA-exposed mice, concentrations that also reduced DMBA-induced DNA damage in mouse and human fibroblasts in vitro. Thus, we have identified DNA damage reduction as a novel mechanism by which rapamycin can prevent cancer, which could lay the foundation for its use as a cancer prevention agent in selected human populations.

SUBMITTER: Dao V 

PROVIDER: S-EPMC4417432 | biostudies-literature | 2015 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Prevention of carcinogen and inflammation-induced dermal cancer by oral rapamycin includes reducing genetic damage.

Dao Vinh V   Pandeswara Srilakshmi S   Liu Yang Y   Hurez Vincent V   Dodds Sherry S   Callaway Danielle D   Liu Aijie A   Hasty Paul P   Sharp Zelton D ZD   Curiel Tyler J TJ  

Cancer prevention research (Philadelphia, Pa.) 20150303 5


Cancer prevention is a cost-effective alternative to treatment. In mice, the mTOR inhibitor rapamycin prevents distinct spontaneous, noninflammatory cancers, making it a candidate broad-spectrum cancer prevention agent. We now show that oral microencapsulated rapamycin (eRapa) prevents skin cancer in dimethylbenz(a)anthracene (DMBA)/12-O-tetradecanoylphorbol-13-acetate (TPA) carcinogen-induced, inflammation-driven carcinogenesis. eRapa given before DMBA/TPA exposure significantly increased tumor  ...[more]

Similar Datasets

| S-EPMC4930727 | biostudies-literature
| S-EPMC3407681 | biostudies-literature
| S-EPMC7106638 | biostudies-literature
| S-EPMC33288 | biostudies-literature
| S-EPMC5429366 | biostudies-literature
| S-EPMC6430824 | biostudies-literature
| S-EPMC7220376 | biostudies-literature
| S-EPMC4726010 | biostudies-literature
| S-EPMC3543983 | biostudies-literature
| S-EPMC3584962 | biostudies-literature